EfA Technologies
Caesarea
About EfA Technologies
EfA’s product: RevDx (Revolutionary Diagnostics), is a mobile, portable, handheld, ,end-point solution that includes an innovative method to perform an automatic computerized microscopy like inspection, including a whole blood sampling and an automatic diagnosis of blood count and other applications to be followed. The product is an easy-to-operate, based on a finger prick and without the need for laboratory conditions and specific preparations. For example, you will be able to make a real-time informed decision about the unnecessary use of antibiotic treatment and the necessity of continued clarification. This product will be an essential device for every point-of-need around the world.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $11.9M
- Funding stage: Seed
- Last round: Seed (Mar 2024)
- Website: efa-technologies.com
- Phone: +972-(0)54-4506334
Industries & Categories
Biotechnology, Health Care, Information Technology, Medical Device, Mobile Apps
Social Profiles
Canonical: https://fsome.com/organization/efa-technologies-61335 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.